During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.
Findings from a phase 2 trial evaluating lenvatinib given at 2 different starting doses, 14 mg versus 18 mg, in combination with everolimus, suggest the lower dose is similar to the standard dose in terms of efficacy and safety with minimal differences observed between the 2 arms.
Significant overall survival and progression-free survival benefits were observed with combination regimens containing immunotherapy in combination with a tyrosine kinase inhibitor, along with tolerable safety in patients with renal cell carcinoma to Suzanne Cole, MD, FACP noted, however, that the cost of these combination can dim the light on the advantages.
Elizabeth Wulff-Burchfield, MD, advises physicians on how to make appropriate treatment decisions for patients with unresectable kidney cancer.
In patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy, the combination of lenvatinib and pembrolizumab achieved antitumor responses, according to results from a phase 2 trial.
In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed key results from the CheckMate-9ER trial in advanced renal cell carcinoma, as well as ongoing trials with the potential to move the landscape further along.
Pavlos Msaouel, MD, PhD, discusses how the treatments and outcomes differ between patients with the rarer disease of renal medullary carcinoma than the more common renal cell carcinoma.
Lenvatinib plus everolimus demonstrated anti-tumor activity as treatment of patients with advanced non-clear cell renal cell carcinoma in the frontline setting, according to findings from a phase 2 clinical trial.
Findings from a planned interim analysis of the Ib/II Study 111 showed that lenvatinib plus pembrolizumab induced a disease control rate of 94% in patients with metastatic clear cell RCC who had disease progression following treatment with a PD-1/PD-L1 inhibitor.
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma.<br />
Patients with advanced renal cell carcinoma assigned to nivolumab plus ipilimumab had a longer treatment-free survival than patients treated with sunitinib. Furthermore, those patients assigned to the combination spent less time experiencing treatment-related adverse events.
In an interview with Targeted Oncology at the IKCS meeting, Gennady Bratslavsky, MD, provided his expert opinion on the optimal first-line therapy for non–clear cell renal cell carcinoma, a topic he debated on with peers at the 2019 International Kidney Cancer Symposium.
Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti–PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.<br />
In an interview with Targeted Oncology during the 2019 International Kidney Cancer Symposium, Yinghong Wang, MD, PhD, MS, discussed the management of gi-related toxicity in patients with kidney cancer from the perspective of a gastrointestinal specialist. She also explained the multidisciplinary collaboration between oncology and gastrointestinal departments to enhance care.
Massachusetts General Hospital in Boston established its immunotherapy toxicity service care team in part because of the experience of David M., a patient treated there for metastatic melanoma that spread to the lung and brain.
Treating clear cell renal cell carcinoma with immune checkpoint inhibitors resulted in vascular changes that may make these tumors more vulnerable to combinations of ICIs and VEGF inhibitors, according to data presented at the 18th International Kidney Cancer Symposium.